Request Demo
Lexicon poaches BMS' Tom Garner as new commercial lead to help with Inpefa launch
Drug ApprovalExecutive Change
Tom Garner is excited by Lexicon Pharmaceuticals' late-stage pipeline drug LX9211 to market for diabetic peripheral neuropathic pain.
Lexicon Pharmaceuticals sLexicon Pharmaceuticalsoften falling over regulatoLX9211dles for its nediabetic peripheral neuropathic painlly getting an FDA approval this year, it’s now turning to Tom Garner to help shore up the drug’s launch.
Lexicon Pharmaceuticalsart disease and pharma sales chops, having most recently been at Bristol Myers Squibb Inpefa senior vice president and head of the company's U.S. Cardiovascular & Established Brands business unit. That included working on heart drug Eliquis, the most prescribed oral, branded medicine in the U.S., as well as Camzyos, a newly approved therapy for obstructive hypertrophic cardiomyopathy. He’s been at BMS for a mighty 21 years, having served stints at Boehringer Ingelheim and Eli Lilly before that stretch.
His role at Lexicon wheart disease center on Inpefa, the once-daily pill that back in MaBristol Myers SquibbGLT1/SGLT2 inhibitor to reach the market after getting an FDA green light. The med is now licensed to reduce the risk of heart failure in adults who have had the condition or have Type 2 diabetes, chronic kidney disease or oCamzyosrdiovascular risk factors.obstructive hypertrophic cardiomyopathyBoehringer IngelheimEli Lilly
It has been Lexiconng and sometimes dark pathInpefahe drug to reach the finish line. In 2019, following an SGLT1/SGLT2 inhibitorSGLT1/SGLT2om an advisory committee, what was then just knoFDAas sotagliflozin was rejected by the FDA to treat Type 1 diaheart failures who can’t control their blood sugar with insType 2 diabeteschronic kidney disease
A year later, when Lexicon appealed the decision, the regulator swatted it back again, citing the risk of diabetes ketoacidosis.sotagliflozinFDAType 1 diabetes
In between the FDA Lexiconons, regulators in Europe approved sotagliflozin as Zynquista for Type 1 diabetediabetes ketoacidosis, however, the holders of Zynquista’s marketing rights in Europe, Guidehouse Germany GmbH, withdrew the marketing authorization, saying it did not wish to commercialize the product.
Then, as LexicoFDApproached its bid to treat heart failure insotagliflozinnts Zynquistathe cType 1 diabetests application to work through what it termed “technical issues,” though these were ulGuidehouse Germany GmbH
Inpefa joLexicontrong field of SGLT2 inhibitoheart failure another that was approved earlier this year—TheracosBio’s Brenzavvy. Blockbusters that rule the market are Boehringer Ingelheim and Eli Lilly’s Jardiance, which generated sales of $6.1 billion in 2021, and AstraZeneca’s Farxiga, which rung up $4.4 billion in revenue last year.
It will be a tough market battlSGLT2t one that Lexicon believes Garner can take on.TheracosBioBoehringer IngelheimEliLillyAstraZenecaFarxiga
“His overall breadth and depth of commercial anLexiconal management experience, with notable success in the cardiovascular space and leading launches, makes him a particularly valuable addition to our management team as we continue to drive the launch of Inpefa (sotagliflozin) for the treatment of heart failure,” said Lonnel Coats, Lexicon’s CEO, in a press release.“As the leader of our commercial organization, Mr. Garner will have a critical role in ensuring we are effectively executing on our launch strategy for Inpefa and delivering against the promise we believe this differentiated brand can have for patients."
"I am very enthusiastic about joining the Lexicon leadership team and leading the commercial organization,” said Garner, adding that he is “particularly excited to leverage my expertise for the ongoing launch of Inpefa.” He is also eyeing the “potential oInpefa (sotagliflozin)exicon’s late-stage piheart failureX9211 to market for diLexiconperipheral neuropathic pain. He said that the med “is what attracted me to Lexicon, and I cannot wait to step into this role and get started.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.